Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABBV-932 in healthy Chinese adults
NCT07024797Phase 1Completed
- Sponsor
- AbbVie Inc.
- Start
- Aug 2025
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ABBV-932 (3 arms), sponsored by AbbVie Inc. Primary endpoints: Maximum Plasma Concentration of ABBV-932 at 43 days, Time to Maximum Plasma Concentration of ABBV-932 at 43 days and 11 more. Started Aug 2025; status: completed.
02
Drugs
ABBV-932
Beyond the preview
Go deeper on NCT07024797.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07024797.